Integrating molecular docking and biological evaluation of metal-phytochemical complexes in Alzheimer’s disease

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory impairment, and neuronal loss. Its pathogenesis involves multiple interconnected mechanisms, including amyloid-β (Aβ) aggregation, τ hyperphosphorylation, oxidative stress, neuroinflammation, and metal ion dyshomeostasis. Current therapeutic strategies primarily provide symptomatic relief, underscoring the urgent need for multitargeted approaches. Natural products have emerged as promising candidates due to their structural diversity and ability to modulate several pathological pathways simultaneously. Among these, triterpenoid glycosides such as momordicoside L exhibit notable antioxidant and anti-inflammatory properties. Recent advances highlight the potential of metal-phytochemical complexes in enhancing pharmacological efficacy. Complexation with metals such as copper may improve the stability, bioavailability, and biological activity of phytochemicals while modulating metal-induced toxicity associated with AD. Molecular docking studies provide insights into interactions with key targets, while in vitro and in vivo investigations demonstrate improved neuroprotective effects, including enhanced cell viability, reduced inflammatory responses, and cognitive improvement. This review emphasizes the integration of analytical characterization, computational modeling, and biological validation, supporting the development of metal-natural product complexes as innovative multitarget therapeutic agents for AD.

Engvall E, Perlmann P. Enzyme-linked immunosorbent assay (ELISA): quantitative assay of immunoglobulin G. Immunochemistry 1971;8:871-4. DOI: https://doi.org/10.1016/0019-2791(71)90454-X

Mosmann T. Rapid colorimetric assay for cellular growth and survival. J Immunol Methods 1983;65:55-63. DOI: https://doi.org/10.1016/0022-1759(83)90303-4

Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991;82:239-59. DOI: https://doi.org/10.1007/BF00308809

Howes MJ, Perry NS, Houghton PJ. Plants with traditional uses relevant to Alzheimer’s disease. Phytother Res 2003;17:1-18. DOI: https://doi.org/10.1002/ptr.1280

Morris GM, Huey R, Lindstrom W, et al. AutoDock4 and AutoDockTools4. J Comput Chem 2009;30:2785-91. DOI: https://doi.org/10.1002/jcc.21256

Faller P, Hureau C. Bioinorganic chemistry of copper and zinc ions coordinated to amyloid-β peptide. Dalton Trans 2009;7:1080-94. DOI: https://doi.org/10.1039/B813398K

Trott O, Olson AJ. AutoDock Vina. J Comput Chem 2010;31:455-61. DOI: https://doi.org/10.1002/jcc.21334

Meng XY, Zhang HX, Mezei M, Cui M. Molecular docking in drug discovery. Curr Comput Aided Drug Des 2011;7:146-57. DOI: https://doi.org/10.2174/157340911795677602

Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. Br J Pharmacol 2011;162:1239-49. DOI: https://doi.org/10.1111/j.1476-5381.2010.01127.x

Rubio-Perez JM, Morillas-Ruiz JM. Inflammatory process in Alzheimer’s disease. ScientificWorldJournal 2012;2012:756357. DOI: https://doi.org/10.1100/2012/756357

Bush AI. The metal theory of Alzheimer’s disease. J Alzheimers Dis 2012;33:S277-81. DOI: https://doi.org/10.3233/JAD-2012-129011

Erdogan Orhan I. Plant metabolites inhibiting Alzheimer-related enzymes. Curr Med Chem 2012;19:2252-61. DOI: https://doi.org/10.2174/092986712800229032

Meraz-Ríos MA, Toral-Rios D, Franco-Bocanegra D, et al. Inflammatory process in Alzheimer’s disease. Front Integr Neurosci 2013;7:59. DOI: https://doi.org/10.3389/fnint.2013.00059

Ayton S, Lei P, Bush AI. Metallostasis in Alzheimer’s disease. Free Radic Biol Med 2013;62:76-89. DOI: https://doi.org/10.1016/j.freeradbiomed.2012.10.558

Kostova I, Balkansky S. Metal complexes as antioxidants. Curr Med Chem 2013;20:4508-39. DOI: https://doi.org/10.2174/09298673113206660288

Barnham KJ, Bush AI. Biological metals in neurodegeneration. Chem Soc Rev 2014;43:6727-49. DOI: https://doi.org/10.1039/C4CS00138A

Colovic MB, Krstić DZ, Lazarević-Pašti TD, et al. Acetylcholinesterase inhibitors. Curr Neuropharmacol 2013;11:315-35. DOI: https://doi.org/10.2174/1570159X11311030006

Xicoy H, Wieringa B, Martens GJ. SH-SY5Y cell line review. Mol Neurodegener 2017;12:10. DOI: https://doi.org/10.1186/s13024-017-0149-0

Kim AC, Lim S, Kim YK. Metal ion effects on Aβ and tau. Int J Mol Sci 2018;19:128. DOI: https://doi.org/10.3390/ijms19010128

Sharma A, Pachauri V, Flora SJ. Metal-related pharmacology in AD. Front Pharmacol 2018;9:1247. DOI: https://doi.org/10.3389/fphar.2018.01247

de Freitas Silva M, Tranches Dias KS, Gontijo VS, et al. Multi-target drugs for Alzheimer’s. Curr Med Chem 2018;25:3491-525. DOI: https://doi.org/10.2174/0929867325666180111101843

Ghasemi F, Bagheri H, Barreto GE, et al. Effects of curcumin on microglial cells. Neurotox Res 2019;36:12-26. DOI: https://doi.org/10.1007/s12640-019-00030-0

Mullane K, Williams M. Preclinical Models of Alzheimer’s Disease: Relevance and Translational Validity. Curr Protoc Pharmacol 2019;84:e57. DOI: https://doi.org/10.1002/cpph.57

Calis Z, Mogulkoc R, Baltaci AK. Flavonoids in neurodegeneration. Mini Rev Med Chem 2020;20:1475-88. DOI: https://doi.org/10.2174/1389557519666190617150051

Breijyeh Z, Karaman R. Comprehensive review on AD. Molecules 2020;25:5789. DOI: https://doi.org/10.3390/molecules25245789

Knopman DS, Smieva H, Petersen RC, et al. Alzheimer disease overview. Nat Rev Dis Primers 2021;7:33. DOI: https://doi.org/10.1038/s41572-021-00269-y

Ward RJ, Dexter DT, Crichton RR. Iron and neurodegeneration. Int J Mol Sci 2022;23:7267. DOI: https://doi.org/10.3390/ijms23137267

Xu B, Bai L, Chen L, et al. Terpenoids in neuroprotection. Front Pharmacol 2022;13:1036506. DOI: https://doi.org/10.3389/fphar.2022.1036506

Novoa C, Salazar P, Cisternas P, et al. Inflammation context in AD. Biol Res 2022;55:39. DOI: https://doi.org/10.1186/s40659-022-00404-3

Beata BK, Wojciech J, Johannes K, et al. AD biochemical and psychological background. Int J Mol Sci 2023;24:1059. DOI: https://doi.org/10.3390/ijms24021059

Chen Y, Yu Y. Tau and neuroinflammation. J Neuroinflammation 2023;20:165. DOI: https://doi.org/10.1186/s12974-023-02853-3

Cummings J. Alzheimer’s drug development pipeline. Alzheimers Dement 2023;9:e12385.

Kciuk M, Kruczjowska W, Gałęziewska J, et al. AD as type 3 diabetes. Int J Mol Sci 2024;25:11955. DOI: https://doi.org/10.3390/ijms252211955

Cacabelos R. Special Issue: “New Trends in Alzheimer’s Disease Research: From Molecular Mechanisms to Therapeutics: 2nd Edition”. Int J Mol Sci 2025;26:7175. DOI: https://doi.org/10.3390/ijms26157175